An Dr Benjamin Philip Tobhach

Is oinceolaí leighis chliabhraigh é an Dr Benjamin Levy a fheidhmíonn freisin mar stiúrthóir cliniciúil ar oinceolaíocht leighis d'Ionad Ailse Johns Hopkins Sidney Kimmel ag Ospidéal Cuimhneacháin Sibley agus mar ollamh comhlach oinceolaíochta ag Scoil Leighis Ollscoil Johns Hopkins. Oibríonn sé as Ionad Ailse Johns Hopkins Sidney Kimmel in Ospidéal Cuimhneacháin Sibley.

Dr. Levy is a clinician scientist who is interested in novel immunotherapeutic treatments for patients with advanced ailse scamhóg, as well as biomarkers that help identify those patients who are more likely to respond to such medicines. He specialises in thoracic malignancies such as non-small cell lung cancer, small cell lung cancer, thymic malignancies, and ailse ceann agus muineál.

Dr. Levy graduated from the Medical College of Georgia. He completed an internal medicine residency at Georgetown University Hospital, followed by a hematology/oncology fellowship at New York Presbyterian/Weill Cornell Medical Centre, where he received the Department of Medicine Research Fellow of the Year Award and the 2009 American Society of Clinical Oncology Young Investigator Award for his ailse próstatach clinical research. Dr. Levy previously worked as an assistant professor at the Icahn School of Medicine, as the medical director of thoracic oncology for Mount Sinai Health Systems, and as the associate director of Mount Sinai Hospital’s Cancer Trialacha Cliniciúla Oifig.

D'fhóin an Dr. D’fhóin sé ar bhord eagarthóireachta an Journal of Clinical Oncology ar feadh dhá bhliain agus faoi láthair is léirmheastóir ad hoc é d’fhoilseacháin bhreise ar nós Clinical Lung Cancer, The Oncologist, agus Onco target. Le déanaí roghnaíodh an Dr. Tá an Dr.

• Ailse scamhóg
• immunotherapy

Becker DJ, Wisnivesky JP, Grossbard ML, Chachoua A, Camidge DR, Tobhach BP. “Marthanas Mná na hÁise le hArd-Ailse Scamhóg i Ré na Teiripe Coscairí Tyrosine Kinase.” Ailse Scamhóg Chlin. 2017 Eanáir; 18(1):e35-e40. doi: 10.1016/j.cllc.2016.08.008.

Tobhach BP, Rao P, Becker DJ, Becker K. “Ag Ionsaí ar Sprioc Gluaiste: Frithsheasmhacht a Thuiscint agus Dul Chun Cinn a Bhainistiú in Othair Ailse Scamhóg Dhearfach EGFR a Caitear le Coscairí Tyrosine Kinase.” oinceolaíochta (Páirc Williston). 2016 Iúil; 30(7):601-12. Léirmheas.

Tobhach BP, Chioda MD, Herndon D, Longshore JW, Mohamed M, Ou SH, Reynolds C, Singh J, Wistuba II, Bunn PA Jr, Hirsch FR. “Tástáil Mhóilíneach chun Ailse Scamhóg Mhéadastatach Neamh-Bheag na gCeall a Chóireáil: Conas Moltaí Bunaithe ar Fhianaise a Chur i bhFeidhm.” Oncologist. 2015 Deireadh Fómhair;20(10):1175-81. doi: 10.1634/theoncologist.2015-0114.

Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Corn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Tobhach BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS . “Gníomhaíocht agus sábháilteacht nivolumab, coscaire imdhíonachta seicphointe frith-PD-1, d’othair a bhfuil ailse scamhóg squamous neamh-bheag teasfhulangach acu (CheckMate 063): triail aon-láimhe céim 2.” Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9.

Tobhach BP, Becker DJ. “Is é an t-am anois le haghaidh scagadh tomagrafaíocht ríomh dáileog íseal: peirspictíocht oinceolaí leighis.” oinceolaíochta (Páirc Williston). 2014 Samhain;28(11):964-6. Níl achomaireacht ar fáil.